172
Views
4
CrossRef citations to date
0
Altmetric
ORIGINAL RESEARCH

Outcomes and Risk Factors of Bloodstream Infections Caused by Carbapenem-Resistant and Non-Carbapenem-Resistant Klebsiella pneumoniae in China

, , , , , , , , , , & show all
Pages 3161-3171 | Published online: 17 Jun 2022

References

  • Martin RM, Bachman MA. Colonization, infection, and the accessory genome of Klebsiella pneumoniae. Front Cell Infect Microbiol. 2018;8:4. doi:10.3389/fcimb.2018.00004
  • MacKenzie FM, Forbes KJ, Dorai-John T, Amyes SG, Gould IM. Emergence of a carbapenem-resistant Klebsiella pneumoniae. Lancet. 1997;350(9080):783. doi:10.1016/S0140-6736(05)62567-6
  • Clancy CJ, Chen L, Shields RK, et al. Epidemiology and molecular characterization of bacteremia due to carbapenem-resistant Klebsiella pneumoniae in transplant recipients. Am J Transplant. 2013;13(10):2619–2633. doi:10.1111/ajt.12424
  • Hussein K, Raz-Pasteur A, Finkelstein R, et al. Impact of carbapenem resistance on the outcome of patients’ hospital-acquired bacteraemia caused by Klebsiella pneumoniae. J Hosp Infect. 2013;83(4):307–313.
  • Xu L, Sun X, Ma X. Systematic review and meta-analysis of mortality of patients infected with carbapenem-resistant Klebsiella pneumoniae. Ann Clin Microbiol Antimicrob. 2017;16(1):18. doi:10.1186/s12941-017-0191-3
  • Zarkotou O, Pournaras S, Tselioti P, et al. Predictors of mortality in patients with bloodstream infections caused by KPC-producing Klebsiella pneumoniae and impact of appropriate antimicrobial treatment. Clin Microbiol Infect. 2011;17(12):1798–1803. doi:10.1111/j.1469-0691.2011.03514.x
  • Zheng S-H, Cao S-J, Xu H, et al. Risk factors, outcomes and genotypes of carbapenem-nonsusceptible Klebsiella pneumoniae bloodstream infection: a three-year retrospective study in a large tertiary hospital in Northern China. Infect Dis. 2018;50(6):443–451. doi:10.1080/23744235.2017.1421772
  • Hu Y, Ping Y, Li L, Xu H, Yan X, Dai H. A retrospective study of risk factors for carbapenem-resistant Klebsiella pneumoniae acquisition among ICU patients. J Infect Dev Ctries. 2016;10(3):208–213. doi:10.3855/jidc.6697
  • Wu D, Cai J, Liu J. Risk factors for the acquisition of nosocomial infection with carbapenem-resistant Klebsiella pneumoniae. South Med J. 2011;104(2):106–110. doi:10.1097/SMJ.0b013e318206063d
  • Huang W, Qiao F, Zhang Y, et al. In-hospital medical costs of infections caused by carbapenem-resistant Klebsiella pneumoniae. Clin Infect Dis. 2018;67(suppl_2):S225–S230. doi:10.1093/cid/ciy642
  • Zhang Z, Sun Z, Tian L. Antimicrobial resistance among pathogens causing bloodstream infections: a multicenter surveillance report over 20 years (1998–2017). Infect Drug Resist. 2022;15:249–260. doi:10.2147/IDR.S344875
  • Lou T, Du X, Zhang P, et al. Risk factors for infection and mortality caused by carbapenem-resistant Klebsiella pneumoniae: a large multicentre case-control and cohort study. J Infect. 2022;84:637–647. doi:10.1016/j.jinf.2022.03.010
  • Cao Z, Yue C, Kong Q, et al. Risk factors for a hospital-acquired carbapenem-resistant bloodstream infection: a five-year retrospective study. Infect Drug Resist. 2022;15:641–654. doi:10.2147/IDR.S342103
  • Pan H, Lou Y, Zeng L, et al. Infections caused by carbapenemase-producing Klebsiella pneumoniae: microbiological characteristics and risk factors. Microb Drug Resist. 2019;25(2):287–296. doi:10.1089/mdr.2018.0339
  • Giacobbe DR, Del Bono V, Trecarichi EM, et al. Risk factors for bloodstream infections due to colistin-resistant KPC-producing Klebsiella pneumoniae: results from a multicenter case-control-control study. Clin Microbiol Infect. 2015;21(12):1106.e1101–1106.e1108. doi:10.1016/j.cmi.2015.08.001
  • Ben-David D, Kordevani R, Keller N, et al. Outcome of carbapenem resistant Klebsiella pneumoniae bloodstream infections. Clin Microbiol Infect. 2012;18(1):54–60. doi:10.1111/j.1469-0691.2011.03478.x
  • Callahan BJ, Wong J, Heiner C, et al. High-throughput amplicon sequencing of the full-length 16S rRNA gene with single-nucleotide resolution. Nucleic Acids Res. 2019;47(18):e103. doi:10.1093/nar/gkz569
  • CLSI. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing. 32nd ed. 2022: M100–S30.
  • Magiorakos AP, Srinivasan A, Carey RB, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012;18(3):268–281. doi:10.1111/j.1469-0691.2011.03570.x
  • McLaughlin MM, Advincula MR, Malczynski M, Barajas G, Qi C, Scheetz MH. Quantifying the clinical virulence of Klebsiella pneumoniae producing carbapenemase Klebsiella pneumoniae with a Galleria mellonella model and a pilot study to translate to patient outcomes. BMC Infect Dis. 2014;14:31. doi:10.1186/1471-2334-14-31
  • Gu D, Dong N, Zheng Z, et al. A fatal outbreak of ST11 carbapenem-resistant hypervirulent Klebsiella pneumoniae in a Chinese hospital: a molecular epidemiological study. Lancet Infect Dis. 2018;18(1):37–46. doi:10.1016/S1473-3099(17)30489-9
  • Livermore DM. The impact of carbapenemases on antimicrobial development and therapy. Curr Opin Investig Drugs. 2002;3(2):218–224.
  • Hu Y, Liu C, Shen Z, et al. Prevalence, risk factors and molecular epidemiology of carbapenem-resistant in patients from Zhejiang, China, 2008–2018. Emerg Microbes Infect. 2020;9(1):1771–1779. doi:10.1080/22221751.2020.1799721
  • Nordmann P, Cuzon G, Naas T. The real threat of Klebsiella pneumoniae carbapenemase-producing bacteria. Lancet Infect Dis. 2009;9(4):228–236. doi:10.1016/S1473-3099(09)70054-4
  • Falagas ME, Tansarli GS, Karageorgopoulos DE, Vardakas KZ. Deaths attributable to carbapenem-resistant Enterobacteriaceae infections. Emerg Infect Dis. 2014;20(7):1170–1175. doi:10.3201/eid2007.121004
  • Zheng X, Wang J-F, Xu W-L, Xu J, Hu J. Clinical and molecular characteristics, risk factors and outcomes of Carbapenem-resistant bloodstream infections in the intensive care unit. Antimicrob Resist Infect Control. 2017;6:102. doi:10.1186/s13756-017-0256-2
  • Zhang Y, Guo LY, Song WQ, Wang Y, Dong F, Liu G. Risk factors for carbapenem-resistant K. pneumoniae bloodstream infection and predictors of mortality in Chinese paediatric patients. BMC Infect Dis. 2018;18:248. doi:10.1186/s12879-018-3160-3
  • Tian L, Tan R, Chen Y, et al. Epidemiology of Klebsiella pneumoniae bloodstream infections in a teaching hospital: factors related to the carbapenem resistance and patient mortality. Antimicrob Resist Infect Control. 2016;5:48. doi:10.1186/s13756-016-0145-0
  • Liu YM, Li BB, Zhang YY, et al. Clinical and molecular characteristics of emerging hypervirulent Klebsiella pneumoniae bloodstream infections in mainland China. Antimicrob Agents Chemother. 2014;58(9):5379–5385. doi:10.1128/AAC.02523-14
  • Falcone M, Russo A, Iacovelli A, et al. Predictors of outcome in ICU patients with septic shock caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae. Clin Microbiol Infect. 2016;22(5):444–450. doi:10.1016/j.cmi.2016.01.016
  • Liu Q, Li W, Du X, et al. Risk and prognostic factors for multidrug-resistant Acinetobacter baumannii complex bacteremia: a retrospective study in a tertiary hospital of West China. PLoS One. 2015;10(6):e0130701. doi:10.1371/journal.pone.0130701
  • da Silva KE, Maciel WG, Sacchi FPC, et al. Risk factors for KPC-producing Klebsiella pneumoniae: watch out for surgery. J Med Microbiol. 2016;65(6):547–553. doi:10.1099/jmm.0.000254